TITLE

Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment Outcomes

AUTHOR(S)
Simen, Birgitte B.; Simons, Jan Fredrik; Hullsiek, Katherine Huppler; Novak, Richard M.; MacArthur, Rodger D.; Baxter, John D.; Chunli Huang; Lubeski, Christine; Turenchalk, Gregory S.; Braverman, Michael S.; Desany, Brian; Rothberg, Jonathan M.; Egholm, Michael; Kozal, Michael J.
PUB. DATE
March 2009
SOURCE
Journal of Infectious Diseases;3/1/2009, Vol. 199 Issue 5, p693
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important. Objectives. To compare the prevalence of drug-resistant variants detected with standard and ultra-deep sequencing (detection down to 1% prevalence) and to determine the impact of minor resistant variants on virologic failure (VF). Methods. The Flexible Initial Retrovirus Suppressive Therapies (FIRST) Study (N = 1397) compared 3 initial antiretroviral therapy (ART) strategies. A random subset (n = 491) had baseline testing for drug-resistance mutations performed by use of standard sequencing methods. Ultra-deep sequencing was performed on samples that had sufficient viral content (N = 264). Proportional hazards models were used to compare rates of VF for those who did and did not have mutations identified. Results. Mutations were detected by standard and ultra-deep sequencing (in 14% and 28% of participants, respectively; P < .001). Among individuals who initiated treatment with an ART regimen that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (hereafter, "NNRTI strategy"), all individuals who had an NNRTI-resistance mutation identified by ultra-deep sequencing experienced VF. When these individuals were compared with individuals who initiated treatment with the NNRTI strategy but who had no NNRTI-resistance mutations, the risk of VF was higher for those who had an NNRTI-resistance mutation detected by both methods (hazard ratio [HR], 12.40 [95% confidence interval {CI}, 3.41-45.10]) and those who had mutation(s) detected only with ultra-deep sequencing (HR, 2.50 [95% CI, 1.17-5.36]). Conclusions. Ultra-deep sequencing identified a significantly larger proportion of HIV-infected, treatment-naive persons as harboring drug-resistant viral variants. Among participants who initiated treatment with the NNRTI strategy, the risk of VF was significantly greater for participants who had low- and high-prevalence NNRTI-resistant variants.
ACCESSION #
36666021

 

Related Articles

  • High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. Franzetti, Marco; Lai, Alessia; Roberto Simonetti, Francesco; Bozzi, Giorgio; De Luca, Andrea; Micheli, Valeria; Meraviglia, Paola; Corsi, Paola; Bagnarelli, Patrizia; Almi, Paolo; Zoncada, Alessia; Balotta, Claudia // Journal of Antimicrobial Chemotherapy (JAC);May2012, Vol. 67 Issue 5, p1250 

    Background Transmitted drug resistance (TDR) is mainly restricted to individuals carrying B subtype, with low prevalence among non-B subtypes when grouped together. Subtype F1 is the most frequent non-B variant found in subjects living in Italy, allowing a specific assessment of TDR associated...

  • Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. von Wyl, Viktor; Yerly, Sabine; Böni, Jürg; Bürgisser, Philippe; Klimkait, Thomas; Battegay, Manuel; Bernasconi, Enos; Cavassini, Matthias; Furrer, Hansjakob; Hirschel, Bernard; Vernazza, Pietro L.; Francioli, Patrick; Bonhoeffer, Sebastian; Ledergerber, Bruno; Günthard, Huldrych F. // Clinical Infectious Diseases;4/1/2009, Vol. 48 Issue 7, p979 

    Background. Accurate quantification of the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and results from previous studies vary. We attempted to assess the prevalence and dynamics of resistance...

  • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. Wensinq, Ann Emarie M. J.; Van De Vijver, David A.; Angarano, Gioacchino; Åsjö, Birgitta; Balotta, Claudia; Boeri, Enzo; Camacho, Ricardo; Chaix, Maire-Laure; Costagliola, Dominique; De Luca, Andrea; Derdelinckx, Inqe; Grossman, Zehava; Hamouda, Osamah; Hatzakis, Anqelos; Hemmer, Robert; Hoepelman, Andy; Horban, Andrzej; Korn, Klaus; Kücherer, Claudia; Leitner, Thomas // Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p958 

    Background. Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure...

  • HIV-1 Drug Resistance: Degree of Underestimation by a Cross-Sectional versus a Longitudinal Testing Approach. Harrigan, P. Richard; Wynhoven, Brian; Brumme, Zabrina L.; Brumme, Chanson J.; Sattha, Beheroze; Major, Jennifer C.; de la Rosa, Rafael; Montaner, Julio S. G. // Journal of Infectious Diseases;4/15/2005, Vol. 191 Issue 8, p1325 

    Genotyping of human immunodeficiency virus type 1 (HIV-1) for antiretroviral drug resistance is routinely used both in clinical practice, to guide the selection of options for an individual's antiretroviral therapy, and in epidemiological studies, to estimate levels of antiretroviral drug...

  • HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naîve and first-line treatment failures in Djiboutian patients. Elmi Abar, Aden; Jlizi, Asma; Youssouf Darar, Houssein; Ali Ben Hadj Kacem, Mohamed; Slim, Amine // Diagnostic Pathology;2012, Vol. 7 Issue 1, p138 

    Abstract: In this study we report the prevalence of antiretroviral drug resistant HIV-1 genotypes of virus isolated from Djiboutian patients who failed first-line antiretroviral therapy (ART) and from ART naïve patients. Patients and methods: A total of 35 blood samples from 16 patients who...

  • Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation. Varghese, Vici; Wang, Elijah; Babrzadeh, Farbod; Bachmann, Michael H.; Shahriar, Rajin; Liu, Tommy; Mappala, Svetlana Jean M.; Gharizadeh, Baback; Fessel, W. Jeffrey; Katzenstein, David; Kassaye, Seble; Shafer, Robert W. // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    Background: The HIV-1 nucleoside RT inhibitor (NRTI)-resistance mutation, K65R confers intermediate to high-level resistance to the NRTIs abacavir, didanosine, emtricitabine, lamivudine, and tenofovir; and low-level resistance to stavudine. Several lines of evidence suggest that K65R is more...

  • Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. Chen, Lamei; Lee, Christopher // Biology Direct;2006, Vol. 1, p14 

    Background: HIV can evolve drug resistance rapidly in response to new drug treatments, often through a combination of multiple mutations [1-3]. It would be useful to develop automated analyses of HIV sequence polymorphism that are able to predict drug resistance mutations, and to distinguish...

  • Drug-resistant HIV test boosts therapy. Tanday, Sanjay // GP: General Practitioner;1/12/2007, p2 

    The article reports that according to a new study, a test that can identify drug-resistant strains of HIV in a patient's blood could boost therapy success. The parallel allele-specific sequencing assay was found to be 1,000 times more sensitive than tests currently used to determine drug...

  • Pre-Screening HIV-1 Reverse Transcriptase Resistance Mutations in Subtype B Patients Using a Novel Multiplex Primer Extension Assay. Jakobsen, Martin Roelsgaard; Aggerholm, Anni; J�rgensen, Louise Bruun; Laursen, Alex; �stergaard, Lars // Current HIV Research;Jul2009, Vol. 7 Issue 4, p398 

    Antiretroviral therapy is standard treatment for HIV-infected patients. Such therapy has decreased mortality and morbidity, but treatment success is often jeopardized by the emergence of viral drug resistance. Moreover, in recent years there has been a reported rise in the incidence of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics